For PSS-treated cells, the expression level of MKI67 was reduced to 75.12, 44.38, 55.96 and 61.56% (P ≤ 0.0001 in all BC cell lines) while PL-treated cells lead to the reduction of MKI67 expression of 69.24, 33.89, 50.29 and 72.26% (P ≤ 0.0001 in all BC cell lines) in MCF-7, T47D, MDA-MB-231 and MDA-MB-468, respectively (Fig. 7A). The gene discussed is MKI67; the disease is breast cancer.